[1] NMPA. Notice on Conducting the Safety Re-evaluation of Traditional Chinese Medicine Injections[EB/OL]. (2009-07-16)[2025-12-15].https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20090716152101457.html. [2] NMPA. National Adverse Drug Reaction Monitoring Annual Report (2019)[EB/OL]. (2020-04-13)[2025-12-30]. https://www.nmpa.gov.cn/xxgk/yjjsh/ypblfytb/20200413094901811.html?type=pc&m=. [3] NMPA. National Adverse Drug Reaction Monitoring Annual Report. (2024)[EB/OL]. (2025-04-07)[2025-12-30]. https://www.cdr-adr.org.cn/center_news/202504/t20250407_51076.html. [4] FAN Z, HAN LJ, LIU Y, et al.Analysis on 622 Reports of Adverse Drug Reactions Induced by Traditional Chinese Medicine[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2025, 25(6): 739-741. [5] LIANG AH, YI Y.Thoughts on the Related Issues of Hypersensitivity Evaluation and Risk Control of Traditional Chinese Medicine Injection[J]. Progress in Pharmaceutical Sciences(药学进展), 2020, 44(10): 752-758. [6] YI Y, LI CY, ZHAO Y, et al.A Novel Mouse Allergy Tested Model and Its Application for Traditional Chinese Medicine Injections’ Allergy Evaluation[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2022, 47(13): 3581-3588. [7] LIANG AH, XIE NING, YI Y, et al.Technical Specification for the Detection of Pseudo-Allergic Reactions Induced by Traditional Chinese Medicine Injections, T/CACM 1381-2022[S]. Beijing: China Association of Chinese Medicine, 2022. [8] NMPA.Technical Guidelines for the Study of Drug Irritation, Allergenicity,Hemolytic Potential[EB/OL]. (2014-05-13)[2025-10-06]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/20140513120001448.html. [9] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China-Volume Ⅳ(中华人民共和国药典四部)[M]. Beijing: China Medical Science Press, 2025. [10] USDHHS, FDA, CDER. Guidance for Industry and Reviewers Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers[EB/OL]. (2005-07)[2025-10-06]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers. [11] ZHANG YS, YI Y, LI CY, et al.Preclinical Evaluation of Pseudoallergic Reactions on Chinese Herbal Injections: Study on Animal Strain and Gender Difference[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2015, 40(14): 2717-2722. [12] National Resource Center for Rodent Laboratory Animals. Selection of Experimental Mouse Age in Weeks[EB/OL]. (2022-12-05)[2025-10-06]. https://nrla.nifdc.org.cn/nrla/ztzl/20221205102904162.html. [13] ZHOU HF, LIU YH, WANG P, et al.Analysis of 65 Cases of Adverse Reactions to Traditional Chinese Medicine Injections[J]. Journal of Traditional Chinese Medicine Management(中医药管理杂志), 2024, 32(7): 89-91. [14] WU G, XUE Z, SUO JS, et al.Analysis of 240 Cases of Adverse Drug Reactions/Events Induced by Traditional Chinese Medicine Injections[J]. China Modern Medicine(中国当代医药), 2025, 32(17): 96-100. [15] LI LJY.Monitoring and Evaluation of Adverse Reactions of Hospital Injections[J]. Guide of China Medicine(中国医药指南), 2025, 23(14): 137-140. [16] National Health Commission of the People’s Republic of China. Chinese National Formulary (Volume of Chemical Drugs and Biological Products) (2010 Edition)(中国国家处方集化学药品和生物制品卷2010年版)[M]. Beijing: People’s Military Medical Press, 2010. [17] FDA. Guidance for Industry-Immunotoxicology Evaluation of Investi-gational New Drugs[EB/OL]. (2001-05-11)[2025-10-06]. https://www.federalregister.gov/documents/2001/05/11/01-11879/draft-guidance-for-industry-on-immunotoxicology-evaluation-of-investigational-new-drugs-availability. [18] ICH. ICH S8 Guideline, Immunotoxicity Studies for Human Pharmaceu-Ticals[EB/OL]. (2022-12-05)[2025-10-06]. https://www.ich.org/page/safety-guidelines. [19] YI Y, LI CY, ZHANG YS, et al.Evaluation and Study of Pseudo-Allergic Reactions of Three Kinds of Traditional Chinese Medicine Injections and Its Mechanisms[J]. China Journal of Chinese Materia Medica(中国中药杂志), 2015, 40(14): 2711-2716. [20] YANG QT, WU YN, WANG YX, et al.Evaluation of Anaphylactoid Reactions Induced by Osteopeptide Injections[J]. Chinese Journal of Comparative Medicine(中国比较医学杂志), 2022, 2(2): 53-59. [21] XIANG YH, XI GC, HAN B, et al. Heilongjiang ZBD Pharmaceutical Co., Ltd. A Quality Standard Control System for Shuxuening Injection Based on Safety Studies[J/OL]. (2016-02-28)[2025-10-06]. https://kns.cnki.net/kcms2/article/abstract?v=VYuoLtjwl8Ntc0jz1ALE6DhLUwmcnKqEVcST9doRxxT9LdajJHrpPQTFuitRtskonMWN9_gXvgF4dgoG1BCddrNphBjIBrsjsQ9IZJZpluFA2Q6S4j5tSm24ziZ1BXsxpZND8I6hAsDrucLKIGXX8RxRbIspQyHWMwAGfD7URA4ckFNlr9Q6HQ==&uniplatform=NZKPT&language=CHS. |